The RSV (Respiratory Syncytial Virus) vaccine is currently available with several types licensed and recommended for different groups:
- The first maternal RSV vaccine, ABRYSVO® by Pfizer, was prequalified by WHO in March 2025 to protect infants through maternal vaccination during pregnancy, aiming to prevent RSV disease in infants up to 6 months old. The vaccine is being rolled out in countries and prequalification supports wider global access starting in 2025.
- Adult RSV vaccines such as AREXVY™ (by GSK) became available in U.S. pharmacies on August 17, 2023, and are recommended by CDC for adults 60 and older, especially higher-risk groups. Other vaccines like Moderna's mRESVIA® and Pfizer's ABRYSVO™ are also approved for adults.
- In the UK, RSV vaccines have been available since September 2024 for adults aged 75 and older and pregnant women. There is a phased roll-out in community pharmacies as of June 2025.
- In Ireland and other parts of Europe, RSV immunization for babies (like nirsevimab) is being introduced for newborns and infants starting September 2025, particularly targeting those born during or shortly before the RSV season.
In summary, RSV vaccines are already available for adults (especially older adults) and pregnant women in many countries as of 2024-2025, with broader maternal vaccination and infant immunization programs rolling out in 2025. Access and availability vary by country and target group but maternal RSV vaccines and infant protection measures are expected to expand significantly this year.
